[{"Assets_0_Q2_USD":492447000.0,"CommonStockSharesOutstanding_0_Q2_shares":56637000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-129223000.0,"NetIncomeLoss_1_Q2_USD":-39838000.0,"NetIncomeLoss_2_Q2_USD":-112418000.0,"StockholdersEquity_0_Q2_USD":-137224000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":56407000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":56114000.0,"Ticker":"TBPH","CIK":"1583107","name":"THERAVANCE BIOPHARMA, INC.","OfficialName":"Theravance Biopharma Inc. Ordinary Shares","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"688048421.0","Country":"Cayman Islands","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20190805"}]